HopeStage
Back to all studies
CompletedNCT00277654

Risperidone or placebo for bipolarity with panic or generalized anxiety

About this title

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

Read the official source — NCT00277654
Medication studyAges 18+United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
CincinnatiSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateFebruary 2004
Recruitment status
Completed
Enrollment listed in the registry
111
Sponsor
Lindner Center of HOPE
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00277654
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cincinnati

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lindner Center of HOPE.

Did this study involve medication?

Yes. The study involved medication, including Risperidone.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies